Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis

Company Overview

Eupraxia Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing engineered bacterial therapies for gastrointestinal and liver diseases. The company’s proprietary platform leverages synthetic biology to engineer nonpathogenic microbial strains capable of producing therapeutic molecules directly at sites of disease within the gut. By combining microbiome science with precision genetic engineering, Eupraxia aims to address conditions that have proven difficult to treat with conventional small molecules or biologics.

The company’s pipeline comprises multiple lead programs in early clinical and preclinical development. These candidates are designed to modulate immune and metabolic pathways through localized delivery of bioactive proteins and peptides. Eupraxia’s approach seeks to reduce systemic exposure and off-target effects by confining therapeutic activity to the gastrointestinal tract. Key areas of investigation include inflammatory bowel diseases, cholestatic liver disorders and other chronic GI conditions with high unmet medical need.

Headquartered in Dallas, Texas, Eupraxia Pharmaceuticals went public on the Nasdaq Global Market under the ticker symbol EPRX. The company is led by a team of experienced biopharmaceutical executives and scientists with expertise in synthetic biology, microbiome research and clinical development. Through strategic partnerships and a growing pipeline, Eupraxia aims to advance novel microbial therapies that could transform the treatment landscape for digestive and liver diseases.

Key Stats

• Today's Range: $5.38 to $5.61
• 50-Day Range: $3.79 to $5.84
• 52-Week Range: $2.20 to $6.20
• Volume: 3,393 shs
• Average Volume: 13,393 shs
• Market Capitalization: $192.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Buy

Eupraxia Pharmaceuticals Stock Analysis - MarketRank™

Eupraxia Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat, and ranked 602nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Eupraxia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Eupraxia Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Eupraxia Pharmaceuticals are expected to grow in the coming year, from ($0.67) to ($0.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eupraxia Pharmaceuticals is -7.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eupraxia Pharmaceuticals is -7.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.62% of the float of Eupraxia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Eupraxia Pharmaceuticals has recently decreased by 0.99%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eupraxia Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eupraxia Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.62% of the float of Eupraxia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Eupraxia Pharmaceuticals has recently decreased by 0.99%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.62

News Sentiment

Eupraxia Pharmaceuticals has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Eupraxia Pharmaceuticals this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eupraxia Pharmaceuticals insiders have not sold or bought any company stock.

EPRX Stock Analysis - Frequently Asked Questions

How have EPRX shares performed this year?

Eupraxia Pharmaceuticals' stock was trading at $3.17 at the beginning of the year. Since then, EPRX stock has increased by 68.7% and is now trading at $5.3490.

How were Eupraxia Pharmaceuticals' earnings last quarter?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) posted its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02.

How do I buy shares of Eupraxia Pharmaceuticals?

Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eupraxia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eupraxia Pharmaceuticals investors own include Aeterna Zentaris (AEZS), BlackBerry (BB), Bausch Health Cos (BHC), Bitfarms (BITF), Ballard Power Systems (BLDP), Cardiol Therapeutics (CRDL) and Fury Gold Mines (FURY).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/16/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EPRX
• Previous Symbol: NASDAQ:EPRX
• CIK: 1581178
• Web: www.eupraxiapharma.com
• Phone: 250-590-3968
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Eupraxia Pharmaceuticals: $11.00
• High Price Target: $12.00
• Low Price Target: $9.00
• Potential Upside/Downside: +105.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.50 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -367.73%
• Return on Assets: -112.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.10
• Quick Ratio: 11.10

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 35,960,000
• Free Float: N/A
• Market Cap: $192.35 million
• Optionable: N/A
• Beta: 1.55